HIV-AIDS and Anti-Retroviral Therapy: Awareness, Benefits and Challenges
Keywords:
HIV, AIDS, ART, PLHIV, CD4, viral load, DTG
Abstract
World AIDS Day observed on 1st December 2024 aims for the right to health by addressing the inequalities that hinder progress in ending AIDS. India has a large number of people living with HIV and factors like socioeconomic strata, stigma and lack of awareness, are till hurdles to cross even though the National AIDS Control Organisation (NACO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS) organisation have made significant strides. Here we discuss the HIV prevalence and burden, evolving anti-retroviral therapies, and improvement in life expectancy over the last decade.
References
1. Kumar P, Das C, Kumar A, Sahu D, Rai SK, Godbole S, Arumugam E, P V M L, Dutta S, Devi HS, Vardhana Rao Mendu V, Kant S, Pandey A, Reddy DCS, Mehendale S, Rajan S. Diversity in HIV epidemic transitions in India: An application of HIV epidemiological metrices and
benchmarks. PLoS One. 2022 Jul 18;17(7):e0270886.
2. Frescura L, Godfrey-Faussett P, Feizzadeh A A, El-Sadr W, Syarif O, Ghys PD; on and behalf of the 2025 testing treatment target Working Group. Achieving the 95 95 95 targets for all: A pathway to ending AIDS. PLoS One. 2022 Aug 4;17(8)
3. NACO -SANKALAK (Status of National AIDS and STD Response) 2023; Fifth edition. Available from https://naco.gov.in/sites/default/files/Sankalak%20Booklet.pdf
4. Rewari BB, Mediratta V. How ART Guidelines are Changing over the Years. JIACM 2020; 21(1-2): 66-70.
5. WHO [Internet] Policy brief: update of recommendations on first- and second-line antiretroviral regimens 2019. World Health Organization. Available from https://iris.who.int/handle/10665/325892.
6. Gandhi RT, Bedimo R, Hoy JF, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society–USA Panel. JAMA. 2023;329(1):63–84.
7. Fantauzzi A, Mezzaroma I. Dolutegravir: clinical efficacy and role in HIV therapy. Ther Adv Chronic Dis. 2014 Jul;5(4):164-77.
8. WHO [Internet]. WHO recommends dolutegravir as preferred HIV treatment option in all populations. Updated July 21, 2019. Available from https://www.who.int/news/item/22-07-2019-who-recommends-dolutegravir-as-preferred-hiv-treatment-option-in-all-populations
9. WHO [Internet]. New report documents increase in HIV drug resistance to dolutegravir. March 5, 2024. Available from https://www.who.int/news/item/05-03-2024-new-report-documents-increase-in-hiv-drug-resistance-to-dolutegravir
10. WHO [Internet]. What’s New in Treatment Monitoring: Viral Load and CD4 testing. Updated July, 17, 2017. Available from https://iris.who.int/bitstream/handle/10665/255891/WHO-HIV-2017.22-eng.pdf
benchmarks. PLoS One. 2022 Jul 18;17(7):e0270886.
2. Frescura L, Godfrey-Faussett P, Feizzadeh A A, El-Sadr W, Syarif O, Ghys PD; on and behalf of the 2025 testing treatment target Working Group. Achieving the 95 95 95 targets for all: A pathway to ending AIDS. PLoS One. 2022 Aug 4;17(8)
3. NACO -SANKALAK (Status of National AIDS and STD Response) 2023; Fifth edition. Available from https://naco.gov.in/sites/default/files/Sankalak%20Booklet.pdf
4. Rewari BB, Mediratta V. How ART Guidelines are Changing over the Years. JIACM 2020; 21(1-2): 66-70.
5. WHO [Internet] Policy brief: update of recommendations on first- and second-line antiretroviral regimens 2019. World Health Organization. Available from https://iris.who.int/handle/10665/325892.
6. Gandhi RT, Bedimo R, Hoy JF, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society–USA Panel. JAMA. 2023;329(1):63–84.
7. Fantauzzi A, Mezzaroma I. Dolutegravir: clinical efficacy and role in HIV therapy. Ther Adv Chronic Dis. 2014 Jul;5(4):164-77.
8. WHO [Internet]. WHO recommends dolutegravir as preferred HIV treatment option in all populations. Updated July 21, 2019. Available from https://www.who.int/news/item/22-07-2019-who-recommends-dolutegravir-as-preferred-hiv-treatment-option-in-all-populations
9. WHO [Internet]. New report documents increase in HIV drug resistance to dolutegravir. March 5, 2024. Available from https://www.who.int/news/item/05-03-2024-new-report-documents-increase-in-hiv-drug-resistance-to-dolutegravir
10. WHO [Internet]. What’s New in Treatment Monitoring: Viral Load and CD4 testing. Updated July, 17, 2017. Available from https://iris.who.int/bitstream/handle/10665/255891/WHO-HIV-2017.22-eng.pdf
Published
2025-01-08
How to Cite
Dr. Sagar Koli, & Dr. Varsha Narayanan. (2025). HIV-AIDS and Anti-Retroviral Therapy: Awareness, Benefits and Challenges. The Indian Practitioner, 77(12), 5-7. Retrieved from https://articles.theindianpractitioner.com/index.php/tip/article/view/1827
Section
Editorial
